Facioscapulohumeral Muscular Dystrophy (FSHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Facioscapulohumeral muscular dystrophy (FSHD) stands out as a genetic muscle disorder with a primary impact on facial, shoulder, and upper arm muscles. This condition is categorized into type 1 (FSHD1) and type 2 (FSHD2), presenting identical signs and symptoms but differing in their genetic origins. Initially, FSHD manifests as facial, shoulder girdle, and arm muscle weakness. Facial weakness may lead to restricted lip movements, causing challenges like whistling, using a straw, or puckering the lips. Notably, individuals with FSHD may acquire a distinctive "mask-like" facial appearance. Upper facial weakness can also result in an inability to close the eyes during sleep. FSHD1 is attributed explicitly to abnormal expression of the DUX4 gene, found on chromosome 4 in the D4Z4 region. The DNA in this region usually undergoes hypermethylation and contains 11-100 repeated DNA segments. Notably, each pregnancy involving an affected parent carries a 50% risk of passing on the abnormal gene to the offspring, irrespective of gender.

·       In terms of prevalence, FSHD affects an estimated 5 to 11 cases per 100,000 population in the USA. A substantial majority, around 95%, are classified as FSHD1, with the remaining 5% falling under FSHD2

 

Thelansis’s “Facioscapulohumeral Muscular Dystrophy (FSHD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Facioscapulohumeral Muscular Dystrophy (FSHD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Facioscapulohumeral Muscular Dystrophy (FSHD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Facioscapulohumeral Muscular Dystrophy (FSHD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Facioscapulohumeral Muscular Dystrophy (FSHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Facioscapulohumeral Muscular Dystrophy (FSHD), Facioscapulohumeral Muscular Dystrophy (FSHD) market outlook, Facioscapulohumeral Muscular Dystrophy (FSHD) competitive landscape, Facioscapulohumeral Muscular Dystrophy (FSHD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)